Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Resection Clear all
Recruiting Not applicable Interventional

Safety and Effectiveness of the Akura Thrombectomy System for Use in the Removal of Emboli From the Pulmonary Arteries in Treating Acute Pulmonary Embolism (PE)

NCT06672510
View directory record Official record
Conditions
Pulmonary Embolism Acute
Interventions
ATC
Device
Lead sponsor
Akura Medical
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
12
States / cities
Thousand Oaks, California • Thornton, Colorado • Hartford, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jun 10, 2026, 2:22 PM EDT
Completed Not applicable Interventional

The Presence of a Therapy Dog Reduces Pain and Anxiety During Pediatric Elbow Pin Removal

NCT05830201
View directory record Official record
Conditions
Elbow Injury
Interventions
No Dog Present, Dog is Present
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
3 Years to 10 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 2:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy

NCT04551001
View directory record Official record
Conditions
Colo-rectal Cancer, Polyp of Colon, Adenomatous Polyp of Colon
Interventions
Cold forcep polypectomy, Cold snare polypectomy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Jun 10, 2026, 2:22 PM EDT
Terminated Not applicable Interventional Results available

Restrictive Versus Liberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury

NCT05306964
View directory record Official record
Conditions
Acute Kidney Injury, Fluid Overload, Hypotension, Dialysis; Complications, Critical Illness
Interventions
Restrictive UFnet Rate Strategy, Liberal UFnet Rate Strategy
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Rochester, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jun 10, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

PP-Gemcitabine & External Beam Radiation-Sarcomas

NCT02046304
View directory record Official record
Conditions
Sarcoma
Interventions
Gemcitabine, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Jun 10, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

NCT00003484
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
carmustine, irinotecan hydrochloride, surgical procedure, iodine I 131 monoclonal antibody 81C6
Drug · Procedure · Radiation
Lead sponsor
Darell D. Bigner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Jun 10, 2026, 2:22 PM EDT
Recruiting No phase listed Observational

The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

NCT06146738
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
Interventions
Palliative Care, Tumor biopsy, Tumor resection
Behavioral · Procedure
Lead sponsor
Jasper Gerritsen
Other
Eligibility
18 Years to 90 Years
Enrollment
1,015 participants
Timeline
2023 – 2029
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2023 · Synced Jun 10, 2026, 2:22 PM EDT
Completed Phase 3 Interventional

The Effect of Gum Chewing on Bowel Motility in Post-operative Colon Resection Patients

NCT01613274
View directory record Official record
Conditions
Colon Resection
Interventions
gum chewing, no gum chewing
Other
Lead sponsor
Allina Health System
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Jun 10, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

NCT00027846
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
filgrastim, carboplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy, Mesna, therapeutic conventional surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
140
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 118 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jun 10, 2026, 2:22 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

NCT05002569
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Springdale, Arkansas • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jun 10, 2026, 2:22 PM EDT
Completed Early Phase 1 Interventional

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma

NCT02940483
View directory record Official record
Conditions
Brain Tumor Recurrent
Interventions
5-Azacytidine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Jun 10, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

NCT00025246
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
imatinib mesylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Jun 10, 2026, 2:22 PM EDT
Completed No phase listed Observational

Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence

NCT02070575
View directory record Official record
Conditions
Prostate Cancer
Interventions
blood draw
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
30 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jun 10, 2026, 2:22 PM EDT
Completed Phase 3 Interventional

Does Coffee Consumption Prevent or Shorten Postoperative Ileus After Colon Resection?

NCT01130675
View directory record Official record
Conditions
Postoperative Ileus
Interventions
caffeinated coffee
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Jun 10, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

NCT02225405
View directory record Official record
Conditions
Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions
Cisplatin, Docetaxel, Laboratory Biomarker Analysis, Nintedanib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jun 10, 2026, 2:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

Bronchial NIR Image-guided Resection

NCT03097575
View directory record Official record
Conditions
Sentinel Lymph Node
Interventions
ICG Intervention, Near Infrared Imaging
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 10, 2026, 2:22 PM EDT
Not yet recruiting No phase listed Observational

Real Time Craniotomy Planning Using Mixed Reality

NCT07468370
View directory record Official record
Conditions
Neurosurgery, Surgical Planning, Brain Tumor Adult, Craniotomy Tumor Removal Surgery
Interventions
Mixed Reality Glasses/Viewer, Survey using a questionnaire.
Device · Other
Lead sponsor
Brainlab AG
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jun 10, 2026, 2:22 PM EDT
Terminated Phase 3 Interventional

Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer

NCT00087256
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Celecoxib, placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Jun 10, 2026, 2:22 PM EDT
Completed Not applicable Interventional

Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer

NCT05483075
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
HCP-Guided Exercise Training Program
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jun 10, 2026, 2:22 PM EDT
Recruiting Phase 1 Interventional

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

NCT07075120
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Ipilimumab and Nivolumab, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 10, 2026, 2:22 PM EDT
Terminated Not applicable Interventional Results available

Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery

NCT01958580
View directory record Official record
Conditions
Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
Interventions
Gemcitabine Hydrochloride, Docetaxel, Internal Radiation Therapy, Intensity-Modulated Radiation Therapy, External Beam Radiation Therapy, Laboratory Biomarker Analysis
Drug · Radiation · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Jun 10, 2026, 2:22 PM EDT
Completed No phase listed Observational

Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma

NCT06557291
View directory record Official record
Conditions
BRAF V600 Mutated-Stage III/IV Melanoma
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Jun 10, 2026, 2:22 PM EDT
Recruiting Phase 2 Interventional

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

NCT05111574
View directory record Official record
Conditions
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Urinary System Mucosal Melanoma, Vaginal Melanoma, Vulvar Melanoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nivolumab, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
143
States / cities
Auburn, California • Berkeley, California • Fremont, California + 117 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 10, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

NCT00636168
View directory record Official record
Conditions
High Risk Stage III Melanoma
Interventions
ipilimumab, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 10, 2026, 2:22 PM EDT